Deeper dives on the questions we get asked most: comparing GLP-1s, real Canadian pricing, how telehealth prescribing actually works, and the honest truth about "research-use-only" peptides.
What Health Canada’s January 2026 GLP-1 advisory says, why compounded and “research use only” semaglutide isn’t a shortcut, semaglutide DIN statuses in the Drug Product Database (including 2026 generics), and how to check a pharmacy with SCPP, ACP, or CPhM.
Read the semaglutide-online safety guide →Lilly list prices and illustrative KwikPen cash bands for Winnipeg, Brandon, and Thompson, why Manitoba Pharmacare / EDS does not list tirzepatide like Ozempic, private-plan notes, and Zepbound vs Mounjaro — closes the Prairie Mounjaro cost trio.
Read the Manitoba Mounjaro cost guide →Lilly list prices and illustrative KwikPen cash bands for Calgary, Edmonton, Red Deer, and Lethbridge, why the Alberta Drug Benefit List doesn’t list tirzepatide yet, Alberta Blue Cross private-plan notes, and Zepbound vs Mounjaro in Canada — twin to the SK Mounjaro guide.
Read the Alberta Mounjaro cost guide →Illustrative KwikPen cash bands for Regina, Saskatoon, and Moose Jaw, plus why the Saskatchewan Drug Plan typically does not list tirzepatide yet — twin to the Ozempic SK cost guide.
Read the Saskatchewan Mounjaro cost guide →Illustrative cash-pay bands for Calgary, Edmonton, and Red Deer, plus Alberta Drug Benefit List step therapy / special authorization for type 2 diabetes — twin to the SK cost guide, not the Wegovy AB page.
Read the Alberta cost guide →Published type 2 diabetes criteria, MEPP vs deductible, who can apply, no retroactive coverage, and why Wegovy weight management usually sits outside the public pathway — Winnipeg to rural MB.
Read the Manitoba EDS guide →Async questionnaire vs same-day video. Illustrative visit and medication cost bands, shipping to SK/AB/MB, and when each platform may fit — without a prescription guarantee.
Read the comparison →Public plans generally skip weight-management brands. Some Alberta Blue Cross–administered private plans may consider special authorization. Plain-language steps for Calgary, Edmonton, and beyond.
Read the Alberta guide →Who can submit EDS, how approval letters work, renewals, and why Wegovy for weight management is usually outside the Drug Plan — separate from the cash-price article.
Read the EDS guide →Same class, different molecules, different average results, different Canadian access. A plain-language head-to-head on efficacy, side effects, cost, and coverage for Canadian patients considering Ozempic/Wegovy vs Mounjaro/Zepbound.
Read the comparison →Real pharmacy prices, real SK Drug Plan behaviour, real private-benefit patterns. A ground-truth breakdown of what a Saskatchewan resident actually pays for Ozempic — from Regina to Moose Jaw to rural SK.
Read the cost breakdown →How does a company like Felix or Maple actually prescribe you a GLP-1 without you seeing a doctor in person? Who's the prescriber, who's the pharmacy, and what regulatory framework holds it all together?
Read the explainer →Why "not for human consumption" vials aren't a legal loophole, what Health Canada has actually said about the peptide gray market, and what the honest Canadian alternatives look like.
Read the safety piece →The two-minute eligibility quiz narrows six Canadian clinics down to the ones that fit your province, goal, and budget.
Editorial + affiliate disclosure: Flatland Health is an independent Canadian publisher. Some links to telehealth providers may be affiliate links — if you sign up, we may earn a commission at no extra cost to you. We only list clinics that say they prescribe Health Canada–authorized medications; verify coverage, cost, and eligibility with the provider. Content is for education only and is not medical advice. Read the full disclosure →
